T cells are required for the CMV-induced antileukemia effect after transplant

Blood

Volumn 119, Issue 4, 2012, Pages 1090-1091

  Elmaagacli, Ahmet H ^a   Koldehoff, Michael ^a   Lindemann, Monika ^a   Sonius, Marlene ^a   Ditschkowski, Markus ^a   Steckel, Nina ^a   Beelen, Dietrich W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CYTOMEGALOVIRUS; HUMAN; LETTER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 84856291018     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-386821     Document Type: Letter

References (5)

1. Thomson K, Mackinnon S, and Peggs K. CMV-specific cellular therapy for acute myeloid leukemia? Blood. 2012;119(4):1088-1090.
2. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402-1412.
3. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808-813.
4. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early Cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362(9393):1375-1377. (Pubitemid 37338339)
5. Elmaagacli AH, Peceny R, Steckel N, et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T cell add-back compared to unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2003;101(2):446-453. (Pubitemid 36077562)